featured
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Lancet Oncol 2021 Dec 08;na(na)na, CA Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, PN Munshi, C Casulo, DG Maloney, S de Vos, R Reshef, LA Leslie, I Yakoub-Agha, OO Oluwole, HCH Fung, J Rosenblatt, JM Rossi, L Goyal, V Plaks, Y Yang, R Vezan, MP Avanzi, SS NeelapuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.